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The BMI1 oncogene promotes prostate cancer (PC) progression. High B-cell-specific Moloney murine leukemia virus
integration site 1 (BMI1) expression predicts poor prognosis in PC patients. Recent evidence suggests that BMI1 may also
play a role in docetaxel chemoresistance. However, mechanisms and clinical significance of BMI1-related chemoresistance
have not been investigated. For this purpose, BMI1 was silenced in 2 PC cell lines (LNCaP and DU 145). Cell proliferation and
apoptosis after docetaxel treatment were measured. Guanine oxidation was assessed by in-cell western. Global gene
expression analysis was performed on BMI1 silenced cells. Oncomine database was used to compare in vitro data with gene
expression in PC samples. BMI1 silencing had no effect on cell proliferation but significantly enhanced docetaxel-induced
antitumor activity. Gene expression analysis demonstrated that BMI1 silencing downregulates a set of antioxidant genes.
Docetaxel treatment increased guanine oxidation, whereas the antioxidant N-acetyl cysteine rescued docetaxel-induced cell
death. Examination of clinical datasets revealed a positive correlation of BMI1 and antioxidant gene expression. BMI1-
controlled antioxidant genes were predictive of poor prognosis in PC patients. In conclusion, BMI1 enhances antioxidant
response, thereby allowing PC survival after docetaxel-based chemotherapy. BMI1-controlled antioxidant genes are
overexpressed in aggressive PC and should be tested as predictors of chemotherapy failure.
Prostate cancer (PC) is not a single disease, but an umbrella
under which a plethora of heterogeneous diseases is hidden.
These range from indolent localized tumors, to aggressive
metastatic diseases.1 Metastatic hormone-refractory prostate
cancer (MHRPC) is the most aggressive form and is generally
associated with very poor prognosis. Docetaxel is currently
the only effective drug for MHRPC. Docetaxel is a microtu-
bule-targeting drug that suppresses spindle microtubule dy-
namics and, thus, blocks mitosis and induces apoptosis.2 It
has been shown that docetaxel disrupts centrosome organiza-
tion in the late S, G2 and M phases of the cell cycle. This
results in incomplete mitosis, accumulation of cells in G2/M
phase and cell death. Two large Phase III trials showed that
docetaxel treatment signiﬁcantly improves survival and qual-
ity of life in MHRPC patients.3,4 Unfortunately, the survival
advantage conferred by docetaxel is limited to 2–3 months,
and life expectance for MHRPC is only 18–19 months.
Indeed, after an initial response to docetaxel, 80% of patients
experience rapid disease progression.5 For this reason,
insights into the mechanisms of docetaxel chemoresistance in
PC cells are warranted.
Mechanisms of resistance to docetaxel are still not clear,
although several hypotheses have been proposed. Docetaxel-
induced microtubule damage inactivates the antiapoptotic
protein BCL2, with subsequent triggering of the apoptotic
machinery. For this reason, BCL2 overexpression in PC has
been linked to chemoresistance.2 Keeping with this observa-
tion, activation of the antiapoptotic Akt pathway leads to
docetaxel resistance.6 An additional mechanism of docetaxel
resistance could be due to overexpression of efﬂux drug
transporters. Some members of the ATP-binding cassette
(ABC) transporter family are expressed by PC cells.7 ABC
protein activity is associated with resistance to several
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chemotherapeutic drugs, including docetaxel. Recent evidence
shows that docetaxel antitumor activity is not limited to its
antimitotic effects. Docetaxel is able to trigger reactive oxygen
species (ROS) formation in cancer cells, thus inducing deoxy-
ribonucleic acid (DNA), protein and cell membrane damage.8
ROS seem to play a major role in docetaxel antitumor activ-
ity. Indeed, head and neck carcinoma cells resistant to doce-
taxel displayed an abnormal mitochondrial DNA content and
an enhanced antioxidant response. Interestingly, blocking the
antioxidant response was able to restore docetaxel
sensitivity.9
A putative mediator of PC chemoresistance is the B-cell-
speciﬁc Moloney murine leukemia virus integration site 1
(BMI1) oncogene. BMI1 belongs to the family of Polycomb
group (PcG) genes. PcG proteins are organized in multimeric
complexes, which mediate histone modiﬁcations of speciﬁc
set of genes during cell development.10 BMI1 is a part of the
Polycomb repressive complex 1, which triggers histone H2A
ubiquitylation and gene silencing. BMI1 is responsible for
p16INK4a locus silencing, thus contributing to prostate carci-
nogenesis.11 Although a mechanistic link has not been estab-
lished, BMI1 is thought to silence many other oncosuppres-
sors, particularly in PC cells. For example, BMI1 is essential
for anchorage-independent growth and metastatic spreading
of PC cells.12 This effect is likely mediated by silencing of
several cell adhesion genes.13 In PC samples, BMI1 overex-
pression is associated with high Gleason score and increased
risk of recurrence after prostatectomy.14 In addition, BMI1 is
overexpressed in a subpopulation of PC cells with tumor-ini-
tiating capabilities.15 Microarray data analysis by Glinsky
et al.16 identiﬁed a BMI-1-pathway signature with concordant
proﬁles in normal stem cells and PC metastasis. In the same
study, expression of the BMI1 signature was strongly associ-
ated with poor survival and therapy failure in ﬁve different
types of epithelial neoplasms, including PC.
Recent studies showed that BMI1 silencing enhanced 5-
ﬂuorouracyl antitumor activity in nasopharyngeal carci-
noma.17 This effect seems to be dependent on the inactiva-
tion of antiapoptotic mechanisms, namely a reduced Akt
phosphorylation. In addition, Hedgehog (HH) signaling acti-
vation enhanced ABC transporter expression and docetaxel
resistance in PC cells.18 BMI1 is a well known downstream
effector of HH signaling.19,20 Finally, BMI1 silencing strongly
impairs antioxidant defense in different cell types.21,22 Given
its prominent role in PC carcinogenesis, progression and
prognosis, we sought to investigate the role of BMI1 in PC
response to docetaxel.
Thus, we hypothesized that BMI1 silencing in PC cell
could enhance docetaxel antitumor activity by at least one of
three mechanisms: (i) inactivating antiapoptotic pathways
(Akt phosphorylation); (ii) downregulating ABC transporter
expression; (iii) impairing antioxidant defenses. For this pur-
pose, we silenced BMI1 in 2 MHRPC cell lines: LNCaP
(derived form and androgen receptor-positive tumor) and
DU 145 (derived from and androgen receptor-negative tu-
mor). We investigated putative mechanisms of BMI1-depend-
ent chemoresistance, and we queried Oncomine database to
test the clinical relevance our in vitro ﬁndings.
Our results show that BMI1 silencing impairs antioxidant
defense and sensitizes PC cells to docetaxel. Examination of
clinical datasets conﬁrmed the relationship between BMI1
expression, antioxidant response and PC aggressiveness.
Material and Methods
Cell culture
The MHRPC cell lines LNCaP and DU 145 were obtained
from American Type Culture Collection (Manassas, VA).
According to ATCC, LNCaP cells are derived from a lymph
node metastasis and DU 145 cells from a brain metastasis.
Both cell lines are derived from androgen-independent PCs,
although LNCaP still expresses the androgen receptor.23 Cells
were maintained in RPMI-1640 medium with 10% fetal bo-
vine serum, glutamine (1%), and penicillin-streptomycin
(1%). Docetaxel (Sigma-Aldrich, St. Louis, MO) was dissolved
in dimethyl sulfoxide (DMSO) and diluted in culture me-
dium immediately before use. Final DMSO concentration
never exceeded 0.1%. N-Acetyl cysteine (NAC; Sigma) was
dissolved in sterile water and a-tocopherol (Sigma) was dis-
solved in ethanol and diluted in culture medium immediately
before use. Final concentration for both NAC and a-tocoph-
erol were 20 mM.
Generation of ShBMI1 LNCaP and DU 145 cells
BMI1-silenced cells were generated using the TRIPZ lentiviral
doxycycline inducible Tet-OnV
R
shRNA system (Open Biosys-
tems, Huntsville, AL), after the protocols provided by the
company. They are referred as DU145ShBMI1 and
LNCaPShBMI1 from therein. Nonsilencing-TRIPZ lentiviral
inducible ShRNAmir expressing cell lines (DU145NS and
LNCaPNS) were generated and used as controls in all the
experiments. Experiments were performed after at least 3
days of doxycycline (1 lg/ml) induction.
Assay of cell viability and caspase activity
Number of viable cells and caspase activity were measured
though CellTiter-Glo- and CaspaseGlo luminescent assay
(Promega, Madison, WL) and caspase. Both assays were pre-
viously described.24 For cell viability, three kinds of experi-
ments were performed;
a. To assess cell proliferation after BMI1 silencing, LNCaP
and DU 145 cells (NS and ShBMI1) were plated in
triplicate in 96-well plates (1,000 cells/well). After 1, 3,
5 and 7 days, cell numbers were measured.
b. To assess cell viability after docetaxel treatment, LNCaP
and DU 145 cells (NS and ShBMI1) were plated in
triplicate in 96-well plates (5,000 cells/well). The follow-
ing day, cells were exposed to different concentrations
of docetaxel (1, 10, 100 and 1,000 nM) for 1 hr. After
treatment, cells were allowed to grow in drug-free
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medium for an additional 3 days, as previously
described.25 Cell viability was measured at the end of
the 3 days. Docetaxel concentrations used in our study
are clinically achievable.26 The 1-hr treatment has been
chosen in analogy with the 1-hr clinical infusion of
docetaxel.26
c. To asses the effect of ROS on docetaxel antitumor ac-
tivity, cells were pretreated with NAC (20 mM, as
described24), then exposed to the same docetaxel con-
centration for 1 hr and grown in NAC-containing me-
dium for 3 days.
For (b) and (c), the fraction of proliferating cells and IC50
values relative to untreated cultures were calculated by non-
linear leastsquares curve-ﬁtting.
Western blot
Total protein was isolated from LNCaP and DU 145 (NS and
ShBMI1) cells using RIPA lysis buffer (Thermo Scientiﬁc,
Waltham, MA) and quantiﬁed using the BCA protein assay
kit (Pierce) kit. A total of 30 lg of protein extract was loaded
per lane into a 4 to 20% Tris-glycine gel (Invitrogen, Carls-
bad, CA). For the experiment testing the effects of docetaxel
and antioxidants on caspase and PARP cleavage, the experi-
ment was set up identical to the experiment testing cell via-
bility. Proteins were transferred to a polyvinylidene ﬂuoride
membrane, blocked in 10% nonfat dry milk, 0.1% Tween-20
PBS, incubated with primary (anti-BMI1; Millipore, 1/1,000
dilution; anti actin, Abcam 1/5,000 dilution; anticleaved Cas-
pase 3 (1:1,000), anticleaved Caspase 8 (1:1,000), anticleaved
Caspase 9 (1:1,000), anti-PARP (1:1,000), Akt (1:2,000), and
phospho-Akt (1:1,000) Cell Signaling Technology) and sec-
ondary (LI-COR Biosciences, Lincoln, NE) antibodies and
scanned by the LI-COR Odyssey IR Imaging System.
Gene expression analysis
Total RNA was extracted from NS and ShBMI1 (LNCaP and
DU 145) cells using the TRIZOL REAGENT (Invitrogen).
RNA was retrotranscribed through SuperScript III First-
Strand Synthesis System for RT-PCR (Invitrogen, p/n 18080-
05) using deoxynucleotide triphosphates and following manu-
facturer’s instructions.
Quantitative-RT-PCR (qRT-PCR) was performed through
TaqMan gene expression assays (Applied Biosystems,
Foster City, CA) and a StepOne Real time PCR machine
(Applied Biosystems). Assay numbers were Hs01067802_m1,
Hs00219905_m1, Hs01055362_m1, Hs00180411_m1,
Hs00830226_gH and Hs99999905_m1 for ABCB1, ABCC1,
ABCG2, BMI1, FTL HSP40C1 and GAPDH, respectively. Dif-
ferential gene expression was calculated by the comparative
Ct method.
To test RNA integrity for microarray analysis, we used
Agilent RNA 6000 Nano LabChip Kit (Agilent, p/n 5067-
1511). All analyzed samples had RIN > 9. Ten microgram of
total RNA from LNCaP and DU 145 (NS and ShBMI) cells
was labeled by reverse transcription with Superscript II (Invi-
trogen) and oligo-dT in the presence of Cy3-dUTP for Uni-
versal RNA reference control (Universal Human Reference
RNA Stratagene p/n 740,000) or Cy5-dUTP for the samples.
Whole Human Genome Oligo Microarray 4  44K format
gene expression arrays (Agilent, p/n G4112F) were used for
gene expression studies. The hybridization and washes were
performed using Agilent reagents and following related pro-
tocols, and the slides were scanned on a GenePix 4000B
scanner (Molecular Devices, Sunnyvale, CA). Differentially
expressed genes were identiﬁed by ANOVA analysis of the
replicates using Partek Genomic Suite Package (Partek). Data
were further analyzed through the use of Ingenuity Pathways
Analysis, with statistical methods and threshold described by
the manufacturer (IngenuityVR Systems, www.ingenuity.com).
Unless otherwise indicated, genes that are up- or downregu-
lated more than twofold and genes modulated with a p <
0.01 are referred as ‘‘signiﬁcantly modulated genes.’’
Quantitative immunofluorescence
To measure ROS effects after docetaxel treatment, LNCaP
and DU 145 (NS and ShBMI1) cells were plated on 96-well
plates. For each cell line, cells were treated with docetaxel at
IC50 concentration of NS cells, as described in ‘‘Assay of Cell
Proliferation.’’ After treatment, cells were ﬁxed in methanol
for 15 min, washed in a solution of PBS and 1% ﬁsh oil gela-
tin (PBSG) and incubated in the same solution for 60 min to
block. After blocking, cells were incubated overnight with pri-
mary antibodies (mouse antioxoguanine, Millipore, 1/200
dilution; rabbit antiactin, Abcam, 1/500 dilution) in PBSG.
After washing with PBSG þ 0.1% Tween 20, cells were incu-
bated with IRDye 800CW labeled donkey antimouse and
IRDye 680CW labeled donkey antirabbit antibody (LI-COR
Biotechnology, 1/200 dilution) for 2 h. After washing with
PBSG þ 0.1% Tween 20, cells were scanned with the LI-COR
Odyssey IR Imaging System.
Cell cycle analysis
Cells were seeded at 50% conﬂuence to ensure logarithmic
growth and treated with docetaxel and anitoxidants in the
same manner as described for cell viability assays. Following
treatment, one million cells were ﬁxed in ice cold 70% etha-
nol overnight. Following ﬁxation, cells were centrifuged and
resuspended in PBS containing 40 lg/mL propidium iodide
and 100 lg/ml RNAse A and incubated at 37C for 1 hr.
Meta-analysis for correlation of in vitro data with clinical
data
In vitro data on BMI1 silencing were compared to PC expres-
sion proﬁles derived from Oncomine 4.2 database analysis
tool (http://www.oncomine.org). Oncomine database was also
used to investigate the correlation between antioxidant genes
and PC prognosis. For this purpose, we identiﬁed 22 PC
studies on Oncomine database. We selected genes positively
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correlated to BMI1 based on a correlation coefﬁcient higher
than 0.5. To avoid a duplicated analysis on same samples, we
identiﬁed studies with the same ﬁrst author and analyzed the
one with the highest number of BMI1-correlated genes
(based on correlation coefﬁcient). All statistical values relative
to this meta-analysis were calculated as described by Chin-
naiyan and coworkers.27
Statistical analysis
Unless otherwise speciﬁed, all experiments were done in trip-
licate and were repeated at least twice. Data were expressed
as mean values SE or SD and were analyzed by Student’s
t-test, ANOVA followed by Bonferroni’s multiple comparison
though GraphPad Prism software. The level of signiﬁcance
was set at p < 0.05.
Results
BMI1 silencing in PC cells
To test the effectiveness of our silencing system, we measured
BMI1 mRNA and protein expression in NS and ShBMI1
cells. Both LNCaP and DU 145 ShBMI1 cells exhibited a
more than threefold reduction in BMI1 mRNA levels (Fig.
1a) and a nearly complete BMI1 protein silencing (Fig. 1b).
Cell viability and caspase activity after BMI1 silencing
We ﬁrst tested the hypothesis that BMI1 silencing affects PC
cell proliferation. Cell growth was not signiﬁcantly affected in
BMI1-silenced cells (data not shown). Given these results, we
investigated the effect of BMI1 silencing on docetaxel antitu-
mor activity. As expected, treatment with docetaxel induced a
dose-dependent growth inhibition, with IC50 concentrations
of 6.53 6 1.59 and 22.60 6 2.64 nM (LNCaP NS and DU
145 NS, respectively). BMI1 silencing caused a signiﬁcant
IC50 reduction in both cell lines (2.01 6 0.76 and 9.96 6
1.02 nM, in LNCaP and DU 145, respectively; Fig. 2a). These
results were consistent with cell cycle and apoptosis measure-
ments. Docetaxel-treated NS and ShBMI1 LNCaP cells exhib-
ited a similar cell cycle distribution (Fig. 2b), but BMI1
silencing increased both the number of apoptotic cells, as
measured by ﬂow cytometry (from 41 to 51%) and caspase
3/7 activity (Fig. 2d). On the contrary, BMI1 silencing in
DU145 cells did not enhance docetaxel-induced apoptosis
(data not shown) but increased the percentage of cells
arrested in G2/M phase (from 12 to 23%; Fig. 2c).
Gene expression analysis
Because one possible explanation for BMI1-dependent che-
moresistance may be drug transporter modulation, we inves-
tigated if BMI1 silencing downregulated three ABC transport-
ers involved in docetaxel chemoresistance28 and expressed by
PC cells.7,29 As shown in Supporting Information Figure 1 A,
LNCaP cells expressed much lower ABC transporter mRNA,
compared to DU 145 cells. Interestingly, LNCaP are more
sensitive to docetaxel and express lower BMI1 than DU 145
cells (Figs. 1 and 2). However, BMI1 silencing did not signiﬁ-
cantly modulate ABC transporter expression. Because doce-
taxel resistance has also been linked to induction the Akt
pathway, we also looked at Akt phosphorylation following
BMI1 silencing. Similarly, we found that BMI1 silencing did
not signiﬁcantly reduce Akt phosphorylation in both cell
lines (Supporting Information Fig. 1B).
To dissect the molecular pathways involved in BMI1-de-
pendent chemosensitivity, we compared gene expression pro-
ﬁles of ShBMI1 and NS cells. BMI1 silencing produced signif-
icant modulation of 564 (LNCaP) and 880 (DU 145) genes
(Supporting Information Tables 1 and 2). Our array data
show that BMI1 silencing upregulated 280/564 (49.6%) and
492/879 (55.9%) genes in the two cell lines. To gain func-
tional insights into the consequences of BMI1 silencing, we
analyzed gene categories modulated by BMI1 (Supporting In-
formation Table 3), using Ingenuity Pathway Analysis (IPA)
software. Interestingly, we found that most of the genes
modulated in both cell lines were signiﬁcantly correlated to
cancer (9.3e15 < p < 3.9e2). In particular, 150 and 141
genes in LNCaP and DU 145 cells respectively were corre-
lated to tumorigenesis. We also found that ‘‘cell death’’ and
‘‘cell growth and proliferation’’ were signiﬁcantly affected
(Supporting Information Table 3). As docetaxel sensitivity
Figure 1. BMI1 RNA (a) and protein (b) silencing in PC cells. MWS, molecular weight scale.
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may be mediated by modulation of pro- and antiapoptotic
pathways, we further assessed function and classiﬁcation of
these genes. In both LNCaP and DU 145, we were unable to
identify a signiﬁcant modulation of pro- or anti apoptotic
pathways after BMI1 silencing. These data are consistent with
the similar Akt phosphorylation level in NS and Sh BMI1
cells. Because analysis of classical death pathways was not
able to explain our data on docetaxel activity, we investigated
TOX pathways modulated after BMI1 silencing. This IPA
analysis determines genes expression changes in response to
several kinds of cell stress, including DNA damage, hypoxia
and xenobiotics. Interestingly, BMI1 silencing was able to
modulate ROS-related genes in both cell lines. In particular,
‘‘Oxidative Stress Response’’ genes ranked ﬁrst among signiﬁ-
cantly affected TOX categories (Supporting Information Ta-
ble 4). Keeping with our cell cycle analysis, G2/M transition
genes were also signiﬁcantly modulated. More interestingly,
we found that BMI1 silencing was able to downregulate an
antioxidant gene set in each of the cell lines (Fig. 3a). Among
these, we found classical antioxidant genes (gamma glutamyl
transferase), different heat shock protein (HSP) 40 isoforms
and ferritin light chain (FLT). Notably, BMI1 silencing never
led to an upregulation of antioxidant genes. In DU 145 cells,
this effect was coupled to upregulation of genes involved in
ROS production (MAOA)30 and ROS-dependent apoptosis
(caspase 8)31. Interestingly, BMI1 silencing also upregulated
KEAP1, which is known to inhibit antioxidant response. In
addition, we conﬁrmed a signiﬁcant downregulation of FTL
and HSP40 genes by qRT-PCR.
Role of ROS in docetaxel activity
Because our array data strongly suggested that BMI1 silenc-
ing disrupts antioxidant response in PC cells, we analyzed
ROS production after docetaxel treatment. For this purpose,
we measured oxoguanine levels in NS and ShBMI1 cells.
Oxoguanine is the main product of DNA oxidative damage
and is widely used to measure oxidative stress.32 As expected,
docetaxel treatment induced a 1.5- to 2-fold increase in oxo-
guanine levels (Fig. 3b). More importantly, BMI1 silenced
cells exhibited a signiﬁcantly higher oxoguanine concentra-
tion in both cell lines (Fig. 3b). Finally, to show that ROS
play a crucial role in docetaxel antitumor activity, we treated
BMI1-silenced cells with the antioxidant NAC. As shown in
Figures 3c and 3d, NAC treatment greatly reduced docetaxel-
dependent cell death. These results show that BMI1 silencing
impairs PC antioxidant response, thus enhancing docetaxel
antitumor activity.
To further corroborate our data, we measured PARP and
caspase cleavage in docetaxel treated and untreated cells. In
addition, we evaluated the effect of two antioxidant molecules
(NAC and a-tocopherol) on docetaxel treated cells. Consist-
ent with our previous results, LNCaP cells exhibited greater
PARP and caspases 9 and 7 cleavage after BMI1 silencing
(Fig. 4). In DU 145 cells, we did not detect caspase 9 cleavage
but instead detected caspase 8 cleavage. However, there was
no change in either caspase or PARP cleavage in the BMI1-
silenced cells as compared to the NS DU 145 cells. Impor-
tantly, in both LNCaP and DU 145 cells both antioxidants
were able to rescue docetaxel-treated cells form apoptosis.
Figure 2. Effects of BMI1 silencing on docetaxel activity. (a) IC50 of cells treated at different docetaxel concentrations *p < 0.05, t-test. (b
and c) cell cycle distribution of docetaxel-treated cells. (d) Caspase 3/7 activity in LNCaP cells treated with docetaxel at IC50 concentration
for NS cells **p < 0.01, t-test.
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Gene expression analysis in clinical samples
Finally, we investigated the possible clinical signiﬁcance of
our in vitro ﬁndings. First, we tested the hypothesis that
BMI1 expression is associated with ROS-related genes in PC
samples. We used Oncomine database to investigate global
gene expression data from 22 independent studies involving
20 to 596 PC samples of different stage and grade. We iden-
tiﬁed 1207 genes positively correlated to BMI1. We then ana-
lyzed, through IPA, the TOX pathways associated to BMI1 in
clinical samples. As shown in Table 1, ‘‘Oxidative Stress
Response’’ genes were signiﬁcantly correlated with BMI1
expression. Among these genes, we found two isoforms of
HSP40, EPHX1 and GST. When we compared oxidative
stress related genes modulated by BMi1 in PC cell lines (Sup-
porting Information Table 5) and in clinical samples (Sup-
porting Information Table 6) we found a very signiﬁcant
overlap (odds ratio: 488.2, p ¼ 8.1e8, Oncomine analysis).
Moreover, in clinical samples, BMI1 expression was signiﬁ-
cantly correlated with ‘‘Hypoxia-Inducible Factor-Signalling,’’
which is also involved in ROS metabolism.
Both in vitro and clinical data indicated that BMI1 con-
trols a set of antioxidant genes in PC cells. Our IPA analysis
generated a BMI1-dependent antioxidant signature (BAS)
composed of 19 genes (Supporting Information Table 5).
Given the prominent role of BMI1 in PC pathogenesis and
progression, we investigated if this antioxidant signature had
a prognostic signiﬁcance. Using the Oncomine database, we
found 3 studies in which the BAS was signiﬁcantly correlated
with PC clinical features (Table 2). In these studies, the sig-
nature was highly predictive of metastasis, shorter recurrence
after prostatectomy and shorter survival. Interestingly, Onco-
mine data showed that high BMI1 expression is predictive of
shorter relapse-free survival in PC (Supporting Information
Fig. 2). These results show that BMI1 controls a set of anti-
oxidant genes in PC and that these genes are activated in
poor prognosis PC.
Discussion
In this article, we showed that BMI1 silencing enhances doce-
taxel antitumor activity in PC and that this effect is mediated
by ROS production. As a part of Polycomb repressive com-
plex 1, BMI1 can silence several genes in different cellular
contexts. In PC, BMI1 is crucial for tumor progression and
metastatic spreading.11,12 In addition, BMI1 expression is
higher in a small fraction of PC cells with tumor initiating
abilities, which may be the seeds of chemoresistance, metasta-
sis and recurrence.15 Clinical data strongly suggest that BMI1
expression is a poor prognostic indicator in PC patients.14
Despite all these indications, very little is known about the
pathways controlled by BMI1 in PC. In addition, it has been
shown that BMI1 enhances chemo- and radio-resistance in
nasopharyngeal carcinoma cells.17,33 For this reason, we
Figure 3. Role of ROS in docetaxel antitumor activity. (a) Oxidative stress response genes expression profile after BMI1 silencing;
*confirmed by qPCR. FTL, ferritin light chain; GGT, gamma glutamyl transferase; EPHX, epoxide hydrolase; GPX, glutathione peroxidase;
HSP, heat shock protein; GST, gluthatione S-transferase; HK, hexokinase; MAOA, monoamine oxidase A; CASP8, caspase 8; KEAP1, Kelch-
like ECH associated protein 1. (b) oxoguanine levels (docetaxel treated cells/untreated cells); *p < 0.05, t-test (NS vs. ShBMI1). (c and d)
cell survival after NAC-docetaxel or docetaxel only treatment in ShBMI1 cells; **p < 0.01, ***p < 0.001, t-test (NS vs. ShBMI1).
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investigated the relationship between BMI1 expression and
PC sensitivity to docetaxel. We also compared our in vitro
ﬁndings to clinical data, in an attempt to evaluate its rele-
vance for the development of new strategies to detect and
overcome PC chemoresistance.
BMI1 silencing signiﬁcantly increased docetaxel-dependent
growth arrest (Fig. 2a). In the p53 positive LNCaP cells, this
effect was due to an increased apoptotic activity. In the p53-
mutated DU145 cells, BMI1 silencing enhanced G2/M phase
arrest induced by docetaxel. Interestingly, in both cell lines,
antioxidant drugs like NAC or tocopherol counteracted the
effects of BMI1 silencing (Figs. 3c and 3d).
The chemosensitivity acquired by both cell lines after BMI1
silencing was not mediated by direct apoptotic pathway modu-
lation, as shown for nasopharyngeal carcinoma cells,33 or by
ABC transporter downregulation (Supporting Information Fig.
1). Our results suggest that BMI1 antioxidant role is crucial in
PC cells. Previous studies have shown that BMI1 plays a key
role in maintaining the oxidative stasis of the cell.21,22 In these
models, BMI1 function has been linked to p16 and p53 suppres-
sion, with no association to antioxidant genes. In this article, we
showed that BMI1 silencing signiﬁcantly increased docetaxel-
dependent oxidative stress (Fig. 3b) and that the antioxidants
NAC and a-tocopherol can completely abrogate this effect
(Figs. 3c and 3d). Gene expression analysis showed BMI1 silenc-
ing downregulated antioxidant genes and upregulated pro-oxi-
dant genes (Fig. 3a). These results were supported by clinical
samples data, showing a signiﬁcant association between genes
classiﬁed by IPA as playing a role in ‘‘Oxidative Stress
Response’’ and BMI1. This set comprises genes that protect cells
from oxidative stress, including epoxide hydrolase, superoxide
dismutase and gamma glutamyl transferase. Interestingly, ter-
minal caspase activity was increased after BMI1 silencing.
Although there is a diversity of oxidative stress-related
genes regulated in these samples, HSP 40 genes are common
to all datasets. HSP 40 is a family of co-chaperones compris-
ing 41 members. Recent evidence suggests that some HSP 40
isoforms are involved in various aspects of cancer biology
and that their expression is deregulated in many neoplasms.34
In addition, HSP 40 members contribute to inhibition of ap-
optosis, protection from oxidative stress, and maintenance of
the mitochondrial membrane potential.35 In view of our
results, it would be interesting to further explore the relation-
ship between HSP 40, BMI1 and PC progression.
The putative relationship between BMI1 antioxidant genes
and PC aggressiveness is further supported by clinical data,
showing a correlation between BMI1-dependent antioxidant
signature (BAS) and PC aggressiveness. In particular, three
independent studies show that BAS is predictive of metasta-
sis, recurrence after prostatectomy and shorter survival. Inter-
estingly, BMI1 expression is an independent predictor of
shorter disease-free survival after prostatectomy.14 This rela-
tionship is conﬁrmed by Oncomine data (Supporting Infor-
mation Fig. 2). A recent meta-analysis on PC patients found
that a shorter time of PC progression is predictive of poor
response to docetaxel.36 Our ﬁndings suggest that a subset of
Figure 4. PARP and caspase cleavage in docetaxel-treated cells.
NAC, N-acetyl cysteine, toco, a-Tocopherol.
Table 1. Top TOX pathways in PC samples
Category
Prostate cancer samples
Number of genes p value
Oxidative stress response 17 1.8 E 2
RAR activation 14 2.6 E 2
HIF signaling 11 4.2 E 4
TGF-beta signaling 9 1.0 E 2
G1/S transition 8 2.0 E 3
Significantly modulated genes after BMI1 silencing were analyzed by
IPA software. HIF, hypoxia inducible factor; RAR, retinoic acid receptor.
Table 2. Prognostic role of BAS genes in PC samples
Prediction p value Odds ratio Patients
Metastasis (PC) 0.004 7.7 112
Dead at 5 years (PC) 0.004 7.7 112
Recurrence at 5 years (PC) 0.006 7.0 54
We generated a new oncomine concept, including 19 genes regulated
by BMI1 in PC cells. This antioxidant gene set was confronted with all
PC studies present in the database, to predict significant associations
with clinical features. p Values and odds ratios are calculated based
on Oncomine algorithms and represent the association between
antioxidant gene expression and patient prognosis (we set significance
threshold at p < 0.01).
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PC is more resistant to docetaxel because of higher BMI1
expression and more effective antioxidant response. These
tumors are also characterized by faster progression. Our in
vitro results call for clinical studies on BMI1 expression in
docetaxel-treated PC patients. According to our data, BMI1
should be overexpressed in chemoresistant tumors. Unfortu-
nately, docetaxel is currently used to treat metastatic disease,
which is always unresectable.1 Thus, clinical specimens from
docetaxel-treated PC patients are hard to get.
These results could pave the way to new approaches to
treat and detect chemoresistant PC. In particular, BMI1
expression, as well as the expression of BAS could prove to
be valid predictive indicators of chemosensitivity. These genes
could be used to personalize docetaxel regimens in MHRPC
patients. Recently, some drug targeting histone modiﬁcations
showed an interesting anticancer effect, and several new com-
pounds are being tested.37 In the future, it is conceivable that
speciﬁc inhibitors of Polycomb repressive complex 1 will be
developed. Our results raise the possibility that docetaxel and
Polycomb-targeting drugs could be synergistic in PC cells
and that a combined regimen could improve docetaxel activ-
ity and prevent tumor recurrence.
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